FDA Approves Genglycos, First Therapy for Glycogen Storage Disease Type Ia
The U.S. Food and Drug Administration (FDA) has issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), marking a significant advancement as the first approved therapy for adults and children aged 8 years and older with glycogen storage disease type Ia (GSDIa). This rare inherited genetic disorder arises from a deficiency of the enzyme glucose-6-phosphatase, which is essential for breaking down stored glycogen into glucose. The approval aims to reduce the daily intake of cornstarch, a critical component of dietary management for individuals with this condition.
The accelerated approval pathway allows the FDA to authorize certain drugs intended for serious or life-threatening conditions based on evidence suggesting a potential clinical benefit. "Patients with GSDIa face possible life-threatening complications and have limited treatment options that primarily involve strict dietary management," stated Karim Mikhail, B. Pharm., M.S., acting director of the Center for Biologics Evaluation and Research (CBER). He emphasized that this approval represents a milestone in utilizing gene therapy to enhance the quality of life for those affected by this disorder.
The FDA's decision was based on clinical trial data indicating that Genglycos effectively reduces daily cornstarch intake when combined with an appropriate diet. The reduction in cornstarch intake serves as a surrogate endpoint, and the manufacturer is required to conduct further clinical trials to validate the therapy's long-term effectiveness.
GSDIa is caused by a genetic mutation leading to the absence of the glucose-6-phosphatase (G6PC) enzyme. This enzyme is crucial for releasing free glucose into the bloodstream, which helps maintain stable blood sugar levels during fasting and between meals. Without this enzyme, individuals can experience dangerously low blood sugar levels, particularly when they go too long without eating, leading to severe metabolic complications.
Management of GSDIa typically involves careful medical monitoring, frequent meals, and strict dietary supplementation of uncooked or specially formulated cornstarch to prevent hypoglycemia. Genglycos is designed as a one-time gene therapy that delivers a functional G6PC gene to the liver, aiming to restore the enzyme's function and stabilize blood sugar levels during fasting.
Dr. Megha Kaushal, M.D., MSc., acting deputy director of the CBER Office of Therapeutic Products, noted that Genglycos offers patients and their families a one-time therapy targeting the root cause of the disease. This accelerated approval reflects the FDA's confidence in the existing clinical evidence and its commitment to providing innovative treatments for rare genetic diseases while continuing to gather data on long-term benefits.
The effectiveness of Genglycos was evaluated in a randomized, double-blind, placebo-controlled study involving patients with GSDIa over 48 weeks. Results showed a statistically significant mean reduction in daily cornstarch intake of 31% in patients treated with Genglycos compared to those receiving a placebo. Additionally, there was a mean reduction of one cornstarch dose per day in the Genglycos group versus placebo. However, patients treated with Genglycos also experienced a numerical increase in the percentage of glucose values in the hypoglycemic range compared to the placebo group.
Serious adverse reactions reported among Genglycos-treated patients included anaphylaxis, adrenal insufficiency, high lactate levels, and hypoglycemia. Commonly reported adverse reactions included increased liver enzymes, nausea, headache, constipation, and hyperglycemia. Notably, Genglycos-treated patients showed a higher incidence of hypertriglyceridemia compared to those receiving a placebo. The prescribing information includes warnings regarding the risks of anaphylaxis, liver toxicity, adrenal insufficiency, and potential tumorigenicity. Genglycos is not recommended for use during pregnancy.
The application for Genglycos received a Rare Pediatric Disease Priority Review Voucher, and the FDA has granted it regenerative medicine advanced therapy (RMAT) and Fast Track designations. The approval was awarded to Ultragenyx Pharmaceutical, Inc.




